Don't miss our top 5 cancer-related stories this month, including a guest commentary from an industry leader, our two-part series on trends in cancer research and more!
 
By E. Kevin Hrusovsky, PerkinElmer Inc.
As the complexity and volume of data continue to rise, bioinformatics is emerging as one of the cornerstones of personalized medicine, from enabling discovery and development of novel treatments and diagnostics to facilitating collection, analysis and interpretation of data that ultimately helps an individual patient.
 
By Randall Willis, ddn Features Editor
Aiming beyond the standard of care in oncology
 
By Randall Willis, ddn Features Editor
Are we really making things better for cancer patients?
 
By Jim Cirigliano, ddn Contributing Editor
Araxes Pharma and Janssen Biotech ink oncology drug development deal
 
By Kelsey Kaustinen, ddnFeatures Editor
OSU, Biosortia link up to identify natural products for potential cancer treatments
 
 
 
Biodesix in Phase III trial collaboration with Kadmon
April 2012
SHARING OPTIONS:

BOULDER, Colo.—Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, announced last month a collaboration with Kadmon Corp. LLC to explore the utility of Biodesix's VeriStrat test in a Phase III non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3 and SRC.  
 
The Phase III study is designed to evaluate KD019 compared to erlotinib in patients with stage IIIB/IV NSCLC who have progressed after first- or second-line chemotherapy. It incorporates an exploratory analysis using VeriStrat, a commercially available, blood-based test that is currently used to help physicians guide treatment for patients with non-small cell lung cancer. VeriStrat testing will be performed on serum samples from the study to assess the test's utility in identifying patients with better or worse outcomes following treatment with KD019. As a multiple TKI with superior potency against wild-type EGFR, KD019 is designed to improve overall survival compared to erlotinib.  
 
"We are very pleased to work with Kadmon on this program," says Dr. Paul Beresford, Biodesix's vice president of business development and strategic marketing. "Our successful collaboration may bring a personalized approach to this exciting new therapy."
 
Over the past year, Biodesix has forged multiple partnerships with biopharmaceutical companies to examine VeriStrat's utility with innovative oncology therapies and to discover novel diagnostic tests.  
 
"This collaboration is aligned with our strategic vision to advance leading-edge science and therapies targeting multiple pathways of proliferation and survival in disease," says Dr. John Ryan, chief medical officer of Kadmon.

Back







CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.